Avalo Therapeutics Inc

AVTX | $13.95 7.31% 6.81% 37K

(0.0% 1d) (168.6% 1m) (337.7% 1y) (0.0% 2d) (6.5% 3d) (8.2% 7d) (-11.97% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 14,426,114
https://www.cerecor.com
Sec Filling | Patents | 31 employees

(United States) Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

monoclonal antibodies antibody covid respiratory treatment

add to watch list Paper trade email alert is off

Icecure Medical Ltd

ICCM | $1.22 0.82% 94K

Manufacturing

(0.0% 1d) (2.1% 1m) (-8.3% 1y) (0.0% 2d) (0.0% 3d) (0.8% 7d) (-33.51% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 55,660,589
https://icecure-medical.com
Sec Filling | Patents | n/a employees

Founded in 2006, Israel-based IceCure Medical develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals.

treatment cancer urea israel kidney lung cancer lungs

add to watch list Paper trade email alert is off